{"entity":{"id":"nct05951179","kind":"trial","name":"Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer","aka":[],"tldr":"A phase 2 trial of TARA-002 in bladder & urothelial cancer, run by Protara Therapeutics, now recruiting.","summary":"Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer is a phase 2 interventional study registered as NCT05951179 by Protara Therapeutics, with 131 participants planned, started 2023-09-15 and due to reach its primary completion in 2031-10. Interventions recorded: TARA-002.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05951179","url":"https://clinicaltrials.gov/study/NCT05951179"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["tara-002"],"companies":["protara-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05951179","phase":"2","setting":"A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer","sponsor":"Protara Therapeutics","enrolled":131,"outcomes":[]},"route":"/trials/nct05951179/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"tara-002","kind":"drug","name":"TARA-002","route":"/drugs/tara-002/"}],"company":[{"id":"protara-therapeutics","kind":"company","name":"Protara Therapeutics","route":"/companies/protara-therapeutics/"}]}}